Intra-Cellular Therapies (ITCI) KOL Sees Good Chance of Caplyta Approval by Year End - Jefferies
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $55.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI) after hosting a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
